How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects
Zoledronic acid is more effective than switching from tenofovir in HIV-positive people with low bone mineral density
Frailty in men with HIV linked with bone weakness, muscle loss and large waist
TAF only superior to TDF when used with a boosting agent
Twice the rate of bone loss among ART-treated women than men
People living with HIV in the UK not receiving appropriate monitoring of heart disease risk
Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir
